Extended prophylaxis of venous thromboembolism with idraparinux

Harry R. Buller, Ander T. Cohen, Bruce Davidson, Hervé Decousus, Alex S. Gallus, Michael Gent, Gerard Pillion, Franco Piovella, Martin H. Prins, Gary E. Raskob

Research output: Contribution to journalArticlepeer-review


Background: The extended use of vitamin K antagonists for prophylaxis against venous thromboembolism is often constrained by risk-benefit limitations and inconvenience. We evaluated the efficacy and safety of a 6-month extension of prophylaxis against recurrent venous thromboembolism with idraparinux in patients who had initially received 6 months of prophylaxis with an anticoagulant. Methods: We randomly assigned patients who had completed 6 months of prophylaxis with idraparinux or a vitamin K antagonist and in whom extended anticoagulation was warranted to receive once-weekly injections of 2.5 mg of idraparinux or placebo for 6 months without monitoring. The primary efficacy and safety outcomes were recurrent venous thromboembolism and major bleeding. Results: Of 1215 patients, 6 of 594 (1.0%) in the idraparinux group and 23 of 621 (3.7%) in the placebo group had recurrent venous thromboembolism (P = 0.002). Major bleeding occurred in 11 patients (1.9%) in the idraparinux group and in none in the placebo group (P

Original languageEnglish
Pages (from-to)1105-1112
Number of pages8
JournalNew England Journal of Medicine
Issue number11
Publication statusPublished - Sept 13 2007

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Extended prophylaxis of venous thromboembolism with idraparinux'. Together they form a unique fingerprint.

Cite this